Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci134 in children with growth hormone deficiency
NCT07450001Phase 2Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GenSci134 in growth hormone deficiency (GHD) (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Treatment Emergent Adverse Events at 35 days and Annualized height velocity at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
GenSci134
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07450001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450001.